标签归档：anti

anti-TNBC agent-1

发表于由
回复

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

anti-TNBC agent-1 

anti-TNBC agent-1 是一种有效的抗三阴性乳腺癌 (TNBC) 试剂。anti-TNBC agent-1 对不同的乳腺癌细胞表现出有效的活性，IC50 值范围为 0.20 μM 至 0.27 μM。anti-TNBC agent-1 通过线粒体途径诱导 SUM-159 细胞凋亡 (apoptosis) 并导致 SUM-159 细胞 G1 期阻滞。

anti-TNBC agent-1

anti-TNBC agent-1 Chemical Structure

CAS No. : 2289585-58-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

anti-TNBC agent-1 is a potent anti-triple-negative breast cancer (TNBC) agent. anti-TNBC agent-1 exhibits potent activity against different breast cancer cells with IC50 values ranging from 0.20 μM to 0.27 μM. anti-TNBC agent-1 induces apoptosis of SUM-159 cells through mitochondria pathway and causes G1 phase arrest of SUM-159 cells[1].

体外研究
(In Vitro)

anti-TNBC agent-1 (compound 7) exhibits potent activity against MDA-MB231, SUM-159, MCF-7, Bcap-37, 4T1 cells with IC50 values ranging from 0.20 μM to 0.27 μM. anti-TNBC agent-1 shows 11.6- to 18.6-fold improvement comparing to that of the parent compound parthenolide with IC50 values of 2.68-4.63 μM. anti-TNBC agent-1 is more active than the positive control drug Adriamycin (ADR)[1].
anti-TNBC agent-1 (2 μM and 5 μM; 48 hours; SUM-159 cells) exhibits significant stronger effect on induction of cell apoptosis compared with that of Parthenolide[1].
anti-TNBC agent-1 has selective cytotoxicity against breast cancer cells (IC50=0.22 μM) being compared with 3T3 cells (IC50=8.13 μM)[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

454.51

Formula

C26H30O7
CAS 号

2289585-58-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Ge W, et al. Synthesis and structure-activity relationship studies of parthenolide derivatives as potential anti-triple negative breast cancer agents. Eur J Med Chem. 2019;166:445-469.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

anti-TNBC agent-1

发表于由
回复

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

anti-TNBC agent-1 

anti-TNBC agent-1 是一种有效的抗三阴性乳腺癌 (TNBC) 试剂。anti-TNBC agent-1 对不同的乳腺癌细胞表现出有效的活性，IC50 值范围为 0.20 μM 至 0.27 μM。anti-TNBC agent-1 通过线粒体途径诱导 SUM-159 细胞凋亡 (apoptosis) 并导致 SUM-159 细胞 G1 期阻滞。

anti-TNBC agent-1

anti-TNBC agent-1 Chemical Structure

CAS No. : 2289585-58-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

anti-TNBC agent-1 is a potent anti-triple-negative breast cancer (TNBC) agent. anti-TNBC agent-1 exhibits potent activity against different breast cancer cells with IC50 values ranging from 0.20 μM to 0.27 μM. anti-TNBC agent-1 induces apoptosis of SUM-159 cells through mitochondria pathway and causes G1 phase arrest of SUM-159 cells[1].

体外研究
(In Vitro)

anti-TNBC agent-1 (compound 7) exhibits potent activity against MDA-MB231, SUM-159, MCF-7, Bcap-37, 4T1 cells with IC50 values ranging from 0.20 μM to 0.27 μM. anti-TNBC agent-1 shows 11.6- to 18.6-fold improvement comparing to that of the parent compound parthenolide with IC50 values of 2.68-4.63 μM. anti-TNBC agent-1 is more active than the positive control drug Adriamycin (ADR)[1].
anti-TNBC agent-1 (2 μM and 5 μM; 48 hours; SUM-159 cells) exhibits significant stronger effect on induction of cell apoptosis compared with that of Parthenolide[1].
anti-TNBC agent-1 has selective cytotoxicity against breast cancer cells (IC50=0.22 μM) being compared with 3T3 cells (IC50=8.13 μM)[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

454.51

Formula

C26H30O7
CAS 号

2289585-58-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Ge W, et al. Synthesis and structure-activity relationship studies of parthenolide derivatives as potential anti-triple negative breast cancer agents. Eur J Med Chem. 2019;166:445-469.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

anti-TNBC agent-1

发表于由
回复

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

anti-TNBC agent-1 

anti-TNBC agent-1 是一种有效的抗三阴性乳腺癌 (TNBC) 试剂。anti-TNBC agent-1 对不同的乳腺癌细胞表现出有效的活性，IC50 值范围为 0.20 μM 至 0.27 μM。anti-TNBC agent-1 通过线粒体途径诱导 SUM-159 细胞凋亡 (apoptosis) 并导致 SUM-159 细胞 G1 期阻滞。

anti-TNBC agent-1

anti-TNBC agent-1 Chemical Structure

CAS No. : 2289585-58-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

anti-TNBC agent-1 is a potent anti-triple-negative breast cancer (TNBC) agent. anti-TNBC agent-1 exhibits potent activity against different breast cancer cells with IC50 values ranging from 0.20 μM to 0.27 μM. anti-TNBC agent-1 induces apoptosis of SUM-159 cells through mitochondria pathway and causes G1 phase arrest of SUM-159 cells[1].

体外研究
(In Vitro)

anti-TNBC agent-1 (compound 7) exhibits potent activity against MDA-MB231, SUM-159, MCF-7, Bcap-37, 4T1 cells with IC50 values ranging from 0.20 μM to 0.27 μM. anti-TNBC agent-1 shows 11.6- to 18.6-fold improvement comparing to that of the parent compound parthenolide with IC50 values of 2.68-4.63 μM. anti-TNBC agent-1 is more active than the positive control drug Adriamycin (ADR)[1].
anti-TNBC agent-1 (2 μM and 5 μM; 48 hours; SUM-159 cells) exhibits significant stronger effect on induction of cell apoptosis compared with that of Parthenolide[1].
anti-TNBC agent-1 has selective cytotoxicity against breast cancer cells (IC50=0.22 μM) being compared with 3T3 cells (IC50=8.13 μM)[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

454.51

Formula

C26H30O7
CAS 号

2289585-58-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Ge W, et al. Synthesis and structure-activity relationship studies of parthenolide derivatives as potential anti-triple negative breast cancer agents. Eur J Med Chem. 2019;166:445-469.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Rituximab (anti-CD20)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Rituximab (anti-CD20) 

Rituximab (anti-CD20) 是一种抗 CD20 嵌合单克隆抗体，用于某些自身免疫疾病和癌症的研究。

Rituximab (anti-CD20)

Rituximab (anti-CD20) Chemical Structure

CAS No. : 174722-31-7

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Rituximab (anti-CD20) 的其他形式现货产品:

Rituximab

生物活性

Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer[1].

体外研究
(In Vitro)

Rituximab (anti-CD20) inhibits the proliferation of stimulated human B cells, which is associated with a relative increase of B cells with an activated naive phenotype. Aside from this population shift, there are no major changes in phenotype or cytokine profile of the various B-cell subsets. B cells stimulated in the presence of rituximab induces stronger T-cell proliferation, compared to B cells stimulated in the absence of rituximab[1]. All lymphoma cells tested are equally sensitive to antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-mediated phagocytosis of tumor cells, and rituximab-induced apoptosis. Rituximab (anti-CD20) induces high CDC killing of follicular lymphoma cells[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

A single injection of rituximab or the murine anti-CD20 Ab 1F5, given i.p. 1 day after the tumor, cures 100% of the animals. Depletion of either NK cells or neutrophils or both in tumor-injected animals does not affect the therapeutic activity of the drug. Similarly, rituximab is able to eradicate tumor cells in athymic nude mice, suggesting that its activity is T cell independent[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

144544.44

CAS 号

174722-31-7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Kamburova EG, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012 Feb;12(2):341-50.

    [2]. Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1;101(3):949-54.

    [3]. Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002 Feb 1;99(3):1038-43.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Tocilizumab(Synonyms: 托珠单抗; Anti-Human IL6R, Humanized Antibody)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Tocilizumab (Synonyms: 托珠单抗; Anti-Human IL6R, Humanized Antibody) 纯度: 99.67%

Tocilizumab (Anti-Human IL6R, Humanized Antibody) 是一种抗人白细胞介素-6 受体 (IL-6R) 的中和抗体，可阻止 IL-6 与 IL-6R 的结合，从而抑制经典和反式信号。Tocilizumab 可用于类风湿性关节炎的相关研究。Tocilizumab 在重症 COVID-19 冠状病毒病方面的研究效果显著。

Tocilizumab(Synonyms: 托珠单抗; Anti-Human IL6R, Humanized Antibody)

Tocilizumab Chemical Structure

CAS No. : 375823-41-9

规格 价格 是否有货 数量
1 mg ￥2700 In-stock
5 mg ￥5700 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

生物活性

Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis[1]. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease)[4].

IC50 & Target[1][2]

IL-6

 

体外研究
(In Vitro)

Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-100 ng/mL; 24 hours, 48 hours) inhibits the cell proliferation (growth rate) in a dose-dependent manner, growth rate by HACM is reduced almost completely by 100 ng/mL tocilizumab[2].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (0.001-10,000 μg/ml; 2 days) inhibits Ba/F3-gp130-IL-6R cell proliferation stimulated with hIL-6 with an IC50 of 13.5 ng/ml[1].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1 μM; 6 hours) reduces the phosphorylation of STAT3 in vitro consistent with in vivo SAS cells[3].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-5 μM; 24 hours) significantly reduces VEGF mRNA expression in SAS cells with serum-free medium[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[2]

Cell Line: Human-derived HARA-B cells
Concentration: 1 ng/mL, 10 ng/mL, and 100 ng/mL
Incubation Time: 24 hours, 48 hours
Result: Inhibited the IL-6R expressed on human-derived HARA-B cells.

Cell Cytotoxicity Assay[1]

Cell Line: Ba/F3-gp130-IL-6R cells
Concentration: 0.001–10000 μg/ml
Incubation Time: 2 days
Result: Inhibited Ba/F3-gp130-IL-6R cell proliferation.

Western Blot Analysis[3]

Cell Line: SAS cells
Concentration: 1 μM
Incubation Time: 6 hours
Result: Reduced the phosphorylation of STAT3.

RT-PCR[3]

Cell Line: SAS cells
Concentration: 1-5 μM
Incubation Time: 24 hours
Result: Reduced VEGF mRNA expression.

体内研究
(In Vivo)

Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intravenous injection; 1.0 mg/100 μL; twice a week, three weeks) decreases the volume of each metastatic focus in tocilizumab-injected mouse brains[2].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intraperitoneal injection;100 μg/mL, every 48 hours; 20days) suppresses OSCC progression and suppresses Tumor Angiogenesis[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: A brain metastasis model of lung tumor cells by inoculating HARA-B cells in nude mice[2]
Dosage: 1.0 mg/100 μL
Administration: Intravenous injection; 1.0 mg/100 μL; twice a week, three weeks
Result: Led the volume of each metastatic focus significantly smaller.
Animal Model: SCID mice with SAS cells[3]
Dosage: 100 μg/mL
Administration: Intraperitoneal injection;100 μg/mL; every 48 hours; 20days
Result: Suppressed the growth of advanced tumors.

Clinical Trial

CAS 号

375823-41-9
中文名称

托珠单抗
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011 Dec 16;286(50):42959-70.

    [2]. Mami Noda, et al. IL-6 Receptor Is a Possible Target against Growth of Metastasized Lung Tumor Cells in the Brain. Int J Mol Sci. 2013 Jan; 14(1): 515–526.

    [3]. Shinriki S, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivogrowth of human oral squamous cell carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5426-34.

    [4]. Chi Zhang, et al. Cytokine Release Syndrome in Severe COVID-19: Interleukin-6 Receptor Antagonist Tocilizumab May Be the Key to Reduce Mortality. Int J Antimicrob Agents. 2020 May;55(5):105954.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

金霉素A

发表于由

金霉素A

肽肽抗生素
≥98%

有货

金霉素A

CAS编号 162478-50-4 | 品牌：Jinpan
Aurantimycin A

MSDS

质检证书(CoA)

相似产品

  • 分子式 C38H64N8O14
  • 分子量856.96

货号 (SKU) 包装规格 是否现货 价格 数量
A275592-1mg 1mg 期货 金霉素A  
A275592-5mg 5mg 期货 金霉素A  

基本信息

产品名称 金霉素A
英文名称 Aurantimycin A
规格或纯度 ≥98%
运输条件 超低温冰袋运输
生化机理 肽肽抗生素。细胞具有细胞毒性。抑制革兰氏阳性细菌的生长。抗炎潜力（C5a拮抗剂）。在体外有活性。

一般描述

储存在-20℃。存放在干燥的条件下。该产品最多可存储12个月。

Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.

相关属性

CAS编号 162478-50-4
溶解性 Soluble in DMSO
储存温度 -20°C储存,干燥
分子量 856.96
分子式 C38H64N8O14
品牌 Jinpan
备注 如果有可能，您尽量在同一天配置溶液，并在当天使用完它。但是，如果您需要预先配制储备溶液，我们建议您将溶液等份保存在-20°C的密封小瓶中。通常，这些产品最多可以使用一周。在使用前和打开样品瓶之前，我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度，用法和处理的建议吗？请访问我们的常见问题（FAQ）页面以获取更多详细信息。

麦迪霉素

发表于由

麦迪霉素

10mM in DMSO

有货

麦迪霉素

CAS编号 35457-80-8 | 品牌：Jinpan
Midecamycin

MSDS

质检证书(CoA)

相似产品

  • 分子式 C₄₁H₆₇NO₁₅
  • 分子量814
  • EC号 252-578-0
  • PubChem编号 5128452

货号 (SKU) 包装规格 是否现货 价格 数量
M423587-1ml 1ml 期货 麦迪霉素  

基本信息

产品名称 麦迪霉素
英文名称 Midecamycin
英文别名 Espinomycin A； Medecamycin A1； Platenomycin B1； Rubimycin； Turimycin P3；SF-837; Antibiotic SF-837
规格或纯度 10mM in DMSO
运输条件 超低温冰袋运输

一般描述

Midecamycin 是一种乙酰氧基取代的大环内酯类抗生素，可针对革兰氏阳性和阴性菌。

Midecamycin, an acetoxy-substituted macrolide antibiotic, is tested against gram-positive and gram-negative bacteria.

相关属性

CAS编号 35457-80-8
比旋光度 α23/D -67°, c = 1 in ethanol
折光率 n20D1.54
熔点 155-156° C
沸点 874° C
pKa值 pKₐ: 6.9 in 50% aq ethanol
储存温度 -80℃储存
RTECS OH4730600
分子量 814
分子式 C₄₁H₆₇NO₁₅
EC号 252-578-0
品牌 Jinpan
Smiles CCC(=O)OC1CC(=O)OC(CC=CC=CC(C(CC(C(C1OC)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)OC(=O)CC)(C)O)N(C)C)O)CC=O)C)O)C
PubChem CID 5128452

链脲佐菌素

发表于由

链脲佐菌素

Antineoplastic and Immunosuppressive Antibiotics
10mM in DMSO

有货

链脲佐菌素

CAS编号 18883-66-4(DMSO) | 品牌：Jinpan
Streptozotocin (STZ)

MSDS

质检证书(CoA)

相似产品

  • 分子式 C8H15N3O7
  • 分子量265.22

货号 (SKU) 包装规格 是否现货 价格 数量
S408311-1ml 1ml 期货 链脲佐菌素  

基本信息

产品名称 链脲佐菌素
英文名称 Streptozotocin (STZ)
英文别名 NSC-85998, Streptozocin, U 9889;1-methyl-1-nitroso-3-((2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydro-2H-pyran-3-yl)urea
规格或纯度 10mM in DMSO
运输条件 超低温冰袋运输
生化机理 Streptozotocin (STZ, NSC-85998, Streptozocin, U 9889) is a glucosamine-nitrosourea derivative, which is a DNA-methylating, carcinogenic, antibiotic and diabetes inducing agent. Streptozotocin induces autophagy and apoptosis. Solutions are best fresh-prepared.

一般描述

Information

Streptozotocin (STZ, NSC-85998, Streptozocin, U 9889) is a glucosamine-nitrosourea derivative, which is a DNA-methylating , carcinogenic, antibiotic and diabetes inducing agent. Streptozotocin induces autophagy and apoptosis . Solutions are best fresh-pre
In vitro

Streptozotocin directly methylates DNA and is highly genotoxic, producing DNA strand breaks, alkali-labile sites, unscheduled DNA synthesis, DNA adducts, chromosomal aberrations, micronuclei, sister chromatid exchanges, and cell death. Free radicals are involved in the production of DNA and chromosome damage by Streptozotocin. Streptozotocin is toxic to pancreatic beta cell. Exposed to 15 mM Streptozotocin for 1 hr followed by a 24 hrs recovery period induces apoptosis in murine pancreatic beta cell line, INS-1. Streptozotocin (30 mM) causes the cells to undergo necrosis (22%) as well as apoptosis (17%).

In vivo

Streptozotocin is often used to induce diabetes mellitus in experimental animals. Streptozotocin is selectively accumulated in pancreatic beta cells via the low-affinity GLUT 2 glucose transporter. Streptozotocin (60 mg/kg) injection for 4 month induces rapid degranulation of beta cells without necrosis, development of cataracts and accumulation of glycogen in the proximal convoluted tubules of the kidney. Streptozotocin (100 mg/kg) produces lesions in the exocrine cells of the pancreas, and persistence of small, possibly secretory, granules in the Golgi zone of beta cells in rats of ‘Streptozotocin diabetes’. Streptozotocin is found to be carcinogenic in rats, mice and hamster. A single administration of Streptozotocin is able to induce tumors in kidney, liver, lung, pancreas, uterine and liver tumors in hamster. Intraperitoneally injected with Streptozotocin (100-150 mg/kg) for normotensive Wistar Kyoto rats (WKY) for 12 months induces carcinogenesis with tumors incidence of 70% in liver, 20% in kidney and 10% in liver and kidney.
Cell Data

cell lines：

Concentrations：

Incubation Time：

Powder Purity:≥99%

相关属性

CAS编号 18883-66-4(DMSO)
储存温度 -80℃储存
分子量 265.22
分子式 C8H15N3O7
品牌 Jinpan
Smiles CN(N=O)C(=O)NC1C(O)OC(CO)C(O)C1O

多肽定制Anti-Flt1 Peptide 编码

发表于由

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 Anti-Flt1 Peptide
编码
别名 Anti-Flt1 Peptide
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） GNQWFI
序列（三字母缩写） Gly-Asn-Gln-Trp-Phe-Ile
基本描述
溶解度
分子量 763.86
化学式 C37H49N9O9
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents Anti-Flt1 Peptide 编码
Figures Anti-Flt1 Peptide 编码
Reference
C端
N端
化学桥

多肽定制Anti-Infective Peptides 编码 [940291-10-1]

发表于由

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 Anti-Infective Peptides
编码 [940291-10-1]
别名 Anti-Infective Peptides
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） KSRIVPAIPVSLL-NH2
序列（三字母缩写） H-Lys-Ser-Arg-Ile-Val-Pro-Ala-Ile-Pro-Val-Ser-Leu-Leu-NH2?(trifluoroacetate salt)
基本描述
溶解度
分子量 1391.76
化学式 C65H118N18O15
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents Anti-Infective Peptides 编码 [940291-10-1]
Figures Anti-Infective Peptides 编码 [940291-10-1]
Reference M.G.Scott et al., Nat. Biotechnol., 25, 465 (2007)
C端
N端
化学桥

多肽定制Anti-Inflammatory Peptide 1 编码 [118850-71-8]

发表于由

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 Anti-Inflammatory Peptide 1
编码 [118850-71-8]
别名 Anti-Inflammatory Peptide 1
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） MQMKKVLDS
序列（三字母缩写） H-Met-Gln-Met-Lys-Lys-Val-Leu-Asp-Ser-OH (trifluoroacetate salt)
基本描述
溶解度
分子量 1079.4
化学式 C45H82N12O14S2
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents Anti-Inflammatory Peptide 1 编码 [118850-71-8]
Figures Anti-Inflammatory Peptide 1 编码 [118850-71-8]
Reference L.Miele et al., Nature, 335, 726 (1988) G.Camussi et al., J. Exp. Med. , 171, 913 (1990) V.Calderaro et al., J. Pharmacol. Exp. Ther. , 263, 579 (1992) A.B.Mukherjee, US Pat. Appl. 7-122 379 (Nov. 19) (1997)
C端
N端
化学桥

多肽定制Anti-Inflammatory Peptide 2 编码 [118850-72-9]

发表于由

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 Anti-Inflammatory Peptide 2
编码 [118850-72-9]
别名 Anti-Inflammatory Peptide 2
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） HDMNKVLDL
序列（三字母缩写） H-His-Asp-Met-Asn-Lys-Val-Leu-Asp-Leu-OH (trifluoroacetate salt)
基本描述
溶解度
分子量 1084.3
化学式
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents Anti-Inflammatory Peptide 2 编码 [118850-72-9]
Figures Anti-Inflammatory Peptide 2 编码 [118850-72-9]
Reference L. Miele et al., Nature, 335, 726 (1988) G. Camussi et al., J. Exp. Med. , 171, 913 (1990) V. Calderaro et al., J. Pharmacol. Exp. Ther. , 263, 579 (1992) A.B. Mukherjee, US Pat. Appl. 7-122 379 (Nov. 19) (1997)
C端
N端
化学桥

多肽定制Anti-Inflammatory Peptide 3 编码 [118850-73-0]

发表于由

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 Anti-Inflammatory Peptide 3
编码 [118850-73-0]
别名 Anti-Inflammatory Peptide 3
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） MQMNKVLDS
序列（三字母缩写） H-Met-Gln-Met-Asn-Lys-Val-Leu-Asp-Ser-OH (trifluoroacetate salt)
基本描述 37-residue peptide possessing antibacterial activity against Escherichia coli, pseudomonas aeruginosa, bacillus megaterium and micrococcus luteus at micromolar concentrations.
溶解度
分子量 1065.3
化学式 C43H76N12O15S2
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents Anti-Inflammatory Peptide 3 编码 [118850-73-0]
Figures Anti-Inflammatory Peptide 3 编码 [118850-73-0]
Reference L. Miele et al., Nature, 335, 726 (1988) G. Camussi et al., J. Exp. Med., 171, 913 (1990) V. Calderaro et al., J. Pharmacol. Exp. Ther., 263, 579 (1992) A.B. Mukherjee, US Pat. Appl. 7-122 379 (Nov. 19) (1997)
C端
N端
化学桥

多肽定制Anti-Kentsin net 编码 [73430-00-9]

发表于由

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 Anti-Kentsin net
编码 [73430-00-9]
别名 Anti-Kentsin net
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） TRKR
序列（三字母缩写） Thr-Arg-Lys-Arg
基本描述
溶解度
分子量 559.67
化学式 C22H45N11O6
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents Anti-Kentsin net 编码 [73430-00-9]
Figures Anti-Kentsin net 编码 [73430-00-9]
Reference
C端
N端
化学桥

Nivolumab (anti-PD-1)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Nivolumab (anti-PD-1) 

Nivolumab (anti-PD-1) 是一种 PD-1 人源类 IgG4 抗体类抑制剂，用于晚期（转移性）非小细胞肺癌的研究。

Nivolumab (anti-PD-1)

Nivolumab (anti-PD-1) Chemical Structure

CAS No. : 946414-94-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Nivolumab (anti-PD-1) 的其他形式现货产品:

Nivolumab

生物活性

Nivolumab (anti-PD-1) is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer[1].

体外研究
(In Vitro)

Nivolumab (anti-PD-1) binds to CHO cells expressing PD-1 with an EC50 of 1.66 nM, but does not bind to the parental CHO cell line. Nivolumab (anti-PD-1) binds to PD-1 on activated T cells with an EC50 of 0.64 nM. Nivolumab (anti-PD-1) also inhibits the interaction between PD-1 and its ligands, PD-L1 and PD-L2, with IC50 values of 2.52 and 2.59 nM, respectively. Nivolumab (anti-PD-1) (1.5 ng/mL) can enhance T-cell reactivity in the presence of a T-cell receptor stimulus[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Nivolumab (anti-PD-1) (10 and 50 mg/kg, i.v.) is well tolerated in cynomolgus monkeys. Serum chemistry changes are limited to a reversible 28% decrease in T3 at week 13 in females treated with 50 mg/kg. T4 and TSH levels are unchanged. In males treated with 50 mg/kg, there are no changes in T3, T4, or TSH levels. Nivolumab (anti-PD-1) exposure increases in an approximately dose-proportional manner between 10 and 50 mg/kg, with no substantial sex differences noted[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
CAS 号

946414-94-4
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wang C, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014 Sep;2(9):846-56.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Pembrolizumab (anti-PD-1)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Pembrolizumab (anti-PD-1) 

Pembrolizumab (anti-PD-1) 是一种人源化 IgG4 抗体，为 PD-1 的抑制剂，用于癌症免疫的研究。

Pembrolizumab (anti-PD-1)

Pembrolizumab (anti-PD-1) Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy[1].

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

HIV-1 p24抗原国家参考品_

发表于由
HIV-1 p24抗原国家参考品

  【编号】：YJ220015

  【产品名称】：HIV-1 p24抗原国家参考品

  【规格】：0.5ml/ml

  【价格】：12000元

　　人类免疫缺陷病毒 p24 抗原国家参考品

　　英文名称：National Reference Panel for p24 Antigen of Human Immune-deficiency Virus type 1
　　批号：220015-20150505
　　性状：血浆，液体
　　用途：本参考品由人类免疫缺陷病毒（Human Immune-deficiency Virus，HIV）阴性血浆、HIV-1 型 p24 抗原阳性血浆、HIV-1 病毒培养物稀释于去人纤维血浆等方法制备而成；适用于 HIV-1 p24 抗原检测试剂的质量控制及评价。
　　包装：白色冻存管。
　　规格：本参考品共 44 支样品，组成如下：
HIV-1 p24抗原国家参考品_
　　使用方法及要求：
　　本参考品使用时，应满足：
　　阴性参考品符合率：不得出现阳性反应，阴性符合率（-/-）应为 20/20；
　　阳性参考品符合率：不得出现阴性反应，阳性符合率（+/+）应为 10/10；
　　线性及最低检出量参考品：10 份参考品（L1～L10）中，L1～L9 由 L1（p24抗原含量为 20 IU/mL）进行 2 倍系列稀释制备而成，L10 为稀释用基质血浆。检测时要求为：（1）对 p24 抗原试剂，最低检出量不得高于 1.25 IU/mL 且基质血浆（L10)为阴性反应；若该试剂同时用于 p24 定量测定，则 L1～L5 共 5 份样品测定值统计分析后，线性相关系数（R 值）应≥0.950.（2）对采用酶联免疫法的 HIV 抗原抗体联合检测试剂，最低检出量不得高于 5IU/mL 且基质血浆（L10)为阴性反应；对采用化学发光法、电化学发光法、酶联荧光法、时间分辨免疫荧光分析法的 HIV 抗原抗体联合检测试剂，最低检出量不得高于 2.5IU/mL 且基质血浆（L10)为阴性反应。
　　精密性：p24 抗原试剂检测时，使用抗原精密性参考品；HIV 抗原抗体联合检测试剂检测时，使用抗原抗体精密性参考品；平行检测 10 孔，变异系数（CV值）应≤15％。
　　储藏条件：
　　－20℃或以下。
　　注意事项：
　　1.本参考品未经灭活处理，应按有传染性物品处理，操作应按实验室安全管
　　理条例执行。
　　2.本参考品不含任何防腐剂，应避免微生物污染和生长。
　　3.应避免反复冻融，反复冻融应不超过 3 次。

华枝睾吸虫病IgG抗体检测试剂盒用国家参考品

发表于由
华枝睾吸虫病IgG抗体检测试剂盒用国家参考品

  【编号】：YJ-290001

  【产品名称】：华枝睾吸虫病IgG抗体检测试剂盒用国家参考品

  【规格】：0.2ml/支，21支/套

  【用途】：用于华枝睾吸虫IgG抗体检测试剂盒检测

　　华支睾吸虫病 IgG 抗体检测试剂盒用冻干血清国家参考品

　　英文：National reference Serum for the control of clonorchiasis IgG antibody test
　　批号：290001-201301
　　性状：白色或淡黄色冻干人血清
　　用途：本品系用无菌方法采集华支睾吸虫阴性和阳性血清或血浆，经多家试剂核验确证，用于华支睾吸虫 IgG 抗体定性诊断试剂的质量控制和评价。购买标准品、对照品就到上海金畔生物科技有限公司
　　包装：安瓿
　　规格：本参考品共 21 支样品，组成如下：
华枝睾吸虫病IgG抗体检测试剂盒用国家参考品
　　使用方法和要求：华支睾吸虫 IgG 抗体阴性参考品和阳性参考品用 0.2ml 纯水完全复溶后直接作为样本使用。最低检出限参考品用 0.2ml 纯水完全复溶后用检测为华支睾吸虫阴性血浆或血清倍比稀释后作为样品使用。检测时应满足如下要求：
华枝睾吸虫病IgG抗体检测试剂盒用国家参考品
　　储藏条件：长期保存应置于-20℃以下。
　　注意事项：
　　1. 上述参考品含有取自人类的材料，并且/或潜藏有传染性成分。未经灭活处理，必须视为潜在的污染物质，应按传染性物品处理。
　　2. 使用时应待参考品完全复溶摇匀后方可加样，冻融次数不能超过 3 次。

包虫IgG抗体诊断试剂用冻干免疫血清国家参考品

发表于由
包虫IgG抗体诊断试剂用冻干免疫血清国家参考品

  【编号】：YJ-230029

  【产品名称】：包虫IgG抗体诊断试剂用冻干免疫血清国家参考品

  【规格】：0.5ml/支

  【用途】：用于包虫IgG抗体诊断试剂检定

　　包虫病 IgG 抗体检测试剂用冻干血清国家参考品

　　英文：National reference Serum for the control of Echinococcosis IgG antibody test
　　批号：230029-201001
　　性状：白色或淡黄色冻干人血清
　　用途：本品系用无菌方法采集包虫阴性和阳性血清或血浆，经多家试剂核验确证，用于包虫 IgG 抗体定性诊断试剂的质量控制和评价。
　　包装：安瓿
　　规格：本参考品共 18 支样品，组成如下：
包虫IgG抗体诊断试剂用冻干免疫血清国家参考品
　　使用方法和要求：包虫 IgG 抗体阴性参考品和阳性参考品用 0.5ml 纯水完全复溶后直接作为样本使用。最低检出限参考品用 0.5ml 纯水完全复溶后用检测为包虫阴性血浆或血清倍比稀释后作为样品使用。检测时应满足如下要求：
包虫IgG抗体诊断试剂用冻干免疫血清国家参考品
　　储藏条件：长期保存应置于-20℃以下。
　　注意事项：
　　1. 上述参考品含有取自人类的材料，并且/或潜藏有传染性成分。未经灭活处理，必须视为潜在的污染物质，应按传染性物品处理。
　　2. 使用时应待参考品完全复溶摇匀后方可加样，冻融次数不能超过 3 次。